You are here : Home > Research Centers and Units > IDMIT

"Infectious Diseases Models for Innovative Therapies" (IDMIT) Research Center

Département Infectious Diseases Models for Innovative Therapies - IDMIT

​Led by: Dr. Rojer Le Grand
SecretariatMartine Desmoulins-Villot

Published on 4 September 2018

General Presentation

The IDMIT Research Center of CEA/DRF/I. JACOB is also (according to the HCERES: The High Council for Evaluation of Research and Higher Education), the U1184/IMVA Joint Research Unit (Immunology of Viral infections and autoimmune diseases).



It is a joint scientific research and technological development Unit between CEA, Paris-Saclay/Paris-Sud University, Inserm, Institut Pasteur, ANRS and OncoDesign society. IDMIT is specialized in the field of human infectious diseases and auto-immune diseases.

As shown in the chart below, the IDMIT Department brings together 4 Research Laboratories, 8 Technology Laboratories & Platforms and hosts the start-up Axénis (see IDMIT Organization).


 

T​ransverse section of an axillary lymph node draining the skin site into which a DNA vaccine was injected eight days earlier. The B lymphocytes (in yellow), labeled with an antibody directed against CD20, are located in the follicles at the periphery of the lymph node. CD1a+ dendritic cells (in red) are abundant and located in the T zones of the lymph node. The activated macrophages expressing CD163 (in green) are located in the medullary sinus of the lymph node.



Objectives

The main research and technological development objectives of the IDMIT Department are to contribute to:

  • Better understanding of the complexity of host/pathogen relationships,
  • Explore the complexity of molecular and cellular mechanisms in particular at the level of the immune system implemented during an infectious, inflammatory or auto-immune process,
  • Harnessing the knowledge gained to promote the development of new drugs, innovative therapeutic strategies and also to contribute to the development of new generations of vaccines,
  • Develop preclinical Non-Human Primates (NHP) models of high predictive value of what will happen in humans in terms of infection, inflammation or dysfunction of the immune system,
  • Improve the performance of pre-existing vaccines or treatments,
  • Validate and/or test the efficacy of new therapeutic drugs, or vaccine candidates,
  • Accelerate and promote the transition from preclinical models (NHP) to clinical trials,
  • Ensure relevant technological developments to maintain advanced research.

IDMIT is also involved in various evaluation programs for therapeutic countermeasures against biological threat agents (CBRN programs, collaboration with the IRBA, in connection with the DGA).

Top page